THE BUILDERS / COMPANY RESEARCH
Recursion
Develops computationally informed clinical drug candidates; reported early trial endpoints are not approvals.
Revenue history & outlook
Consolidated annual company revenue; all business lines, not AI-only sales. · USD billion
| Period | Revenue | Classification | Published | Source |
|---|---|---|---|---|
| FY2021 · ended Dec 31, 2021 | ≈0.01 | Reported observation | 2026-08-17 | Stock Analysis / S&P Global |
| FY2022 · ended Dec 31, 2022 | ≈0.04 | Reported observation | 2026-08-17 | Stock Analysis / S&P Global |
| FY2023 · ended Dec 31, 2023 | ≈0.045 | Reported observation | 2026-08-17 | Stock Analysis / S&P Global |
| FY2024 · ended Dec 31, 2024 | ≈0.059 | Reported observation | 2026-08-17 | Stock Analysis / S&P Global |
| FY2025 · ended Dec 31, 2025 | ≈0.075 | Reported observation | 2026-08-17 | Stock Analysis / S&P Global |
| FY2026 · analyst consensus | ≈0.043 | Independent projection | 2026-08-17 | Stock Analysis / S&P Global |
| FY2027 · analyst consensus | ≈0.056 | Independent projection | 2026-08-17 | Stock Analysis / S&P Global |